A blend of expertise, a common culture.


The health agenda is the most critical and high profile in society, but its value also brings enormous complexity and challenge.

Its importance to us as a firm is reflected in the scale of our team and the many years of experience that we bring to bear. We pride ourselves on the breadth of that team both in terms of our ability to support the diversity of the sector and the depth of our legal expertise.

From locally provided primary and community care through to large scale infrastructure projects, we have an intimate knowledge of the healthcare system. When combined with our experience in supporting a broad range of activity across the biotech, medical devices and the burgeoning med tech communities, from start-ups to high profile multinationals, our ability to support and guide the health sector client community is market leading.

The Covid 19 pandemic has stretched healthcare systems like never before. As part of a wide-ranging response, we have advised on the setting up of the emergency mass vaccine centres in the East of Scotland, working with NHS procurement and using our extensive experience to find acceptable short cuts to the established norms.

That experience has been gained across a wide variety of complex and demanding projects in health provision over many years. We regularly act across the diversity of healthcare services, from Primary Care through Acute Medical, major infrastructure projects and into community-based care provision and later life living. We support voluntary mental health services and advised the British Medical Association on financial models to enable GP practices to thrive.

We are active across the health-focused client community from early-stage funders & investors to ultimate operators, and from the NHS and Government providers to private sector interests. The range of our client relationships ensures that we fully understand the priorities of each component part of the healthcare mix and can advise with that context.

We have held roles advising public sector participants, hub companies and lead contractors on significant projects in each of Scotland’s five hub territories, many of which to construct health infrastructure. In 2020 we reached financial close for Hub West Scotland in enabling works for the largest health centre in Scotland and are currently negotiating the Main Works phase.

Our teams continue to go from strength to strength in their highly regarded work in the care home sector, acting for key clients such as Hamberley Care Homes, Sanctuary Group and Impact Healthcare. In 2020 we were also proud to be appointed to the Scottish Care Association's Legal Services Panel, to provide advice to their members.

We operate extensively across the life sciences community - we nurture start-ups and spin-out teams as they seek to push the boundaries of medical science, guiding them through funding rounds and calling on our extensive team for a range of relevant, specialist legal services as they grow. Our market leading Corporate and M&A teams are called on by life science investors and management teams alike, to advise them during their most significant business transactions.

We provide ongoing investment advice to Scottish Enterprise who are leading on a range of developments in the life sciences sector - most recently we acted for them alongside Thairm Bio, in an investment into Pneumagen Limited, a St Andrews University spin-out. Our work extends to the biotech, gene therapy and health advisory communities.

Our Tier 1 ranked teams in Product Liability and Intellectual Property litigation act for many of the multinational giants of the pharmaceutical industry, clearing a path through complex regulatory challenges and managing their disputes. We have been involved in all the large group product liability litigation which has taken place in Scotland over the last decade.

We acted for Merck in the Vioxx litigation in Scotland, one of the biggest pieces of global litigation then active. Our Intellectual Property Litigators have recently advised a global pharmaceutical company through a number of critical patent disputes and our construction and engineering teams act for pharma/life science companies in developing new production facilities.

As healthcare systems face ever growing pressure from crises such as the current pandemic or more gradual, growing threats such as population ageing or antibiotic resistance, technology is becoming increasingly central in making health provision as efficient and accessible as possible.

To support this transition our highly experienced team bring together the Corporate, Technology, Intellectual Property and Regulatory expertise that is so vital to this sector - coupled to a clear, experience-based understanding of how these topics interlink for healthcare focused clients.

We have a stand-out track record in high value and complex medical device cases, making us the “go to” Scottish firm in this area. Our contribution to current major global cases for Smith & Nephew and Medtronic place us in a unique position in the Scottish market.

We have established a strong lead in providing strategic advice on the regulatory regime within the UK and the EU – this work is often highly confidential and is invaluable for our international clients as they develop their market access strategies.

In our recent Corporate activity, we have acted for the founding shareholders of a major provider of health and social care specific software and services - its clinical and care management system is used in over 40 hospitals in the UK both private and NHS.

We also recently advised on the acquisition of a drug discovery software provider to the pharmaceutical and biotech industries. The market for computer aided drug discovery (CADD) is fast-growing, driven by the increasing capabilities and sophistication of software tools that can deliver material cost and time savings for drug developers.

Work Highlights

Bridgepoint Growth

We advised Bridgepoint Growth I with a capital investment into PharmaReview, a UK provider of compliance and copy review services to the life sciences sector.

Welltower Inc

We advised Welltower Inc, a global investor in healthcare real estate, in the Scottish aspects of a £540 million refinance of HC-One’s existing debt facilities, involving a UK-wide portfolio of HC-One operated care homes, with around 50 in Scotland.

Hub West Scotland

We are advising Hub West Scotland on a Design and Build Development Agreement for the £50million development for a new North East Health Hub on a site near Parkhead, Glasgow - the largest health centre in Scotland.

Hamberley Care Homes

We are Scottish advisers to Hamberley Care Homes Group, providing a multi-disciplinary service including advice on property, corporate finance, regulatory, banking, construction and employment law.

Cello Health

We've worked with this leading and fast growing US and European Strategic Healthcare and Life Sciences advisory group for over a decade, supporting them on various matters relating to property, employment and acquisitions. Most recently we advised on the restructure and alignment of a number of their business to form a new technology centric division.

Scottish Enterprise

We provide ongoing investment advice to Scottish Enterprise, which includes a variety of investments in the life science and healthcare sector. Recent transactions include their participation in a £2.4m funding round into Clinspec Diagnostics (an early cancer detection tech pioneer) and a £1.7m funding round into Cumulus Oncology, Europe’s first oncology drug discovery accelerator.

NHS Lothian

We advised NHS Lothian on a Design and Build Development Agreement for the £3million refurbishment of the Panmure St Ann's school building into a health and care centre for Edinburgh’s homeless population.

The Wellcome Trust

We advised the Wellcome Trust, a charity dedicated to medical research and new drug discoveries, on the Scots law aspects of its recommended public takeover of Urban&Civic plc, a regeneration-focused property development company.

Highlands & Islands Enterprise

We are advising Highlands & Islands Enterprise on the procurement and construction of the Life Sciences Innovation Centre, consisting of a teaching and research facility for the University of the Highlands & Islands and commercial space for Highlands & Islands Enterprise.

Aedifica

We advised Aedifica, a pan European Healthcare REIT, on the Scots law aspects of the acquisition of a substantial UK care home portfolio comprising 92 care homes, of which 10 were located in Scotland.

US MedTech

We advised a US based MedTech company that has pioneered unique medical devices and therapies in relation to a strategic alliance and consulting agreement with a leading Scottish University.